Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,699 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors.
Schoenfeld AJ, Lee SM, Doger de Spéville B, Gettinger SN, Häfliger S, Sukari A, Papa S, Rodríguez-Moreno JF, Graf Finckenstein F, Fiaz R, Catlett M, Chen G, Qi R, Masteller EL, Gontcharova V, He K. Schoenfeld AJ, et al. Among authors: he k. Cancer Discov. 2024 Aug 2;14(8):1389-1402. doi: 10.1158/2159-8290.CD-23-1334. Cancer Discov. 2024. PMID: 38563600 Free PMC article. Clinical Trial.
Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Qin A, Zhao S, Miah A, Wei L, Patel S, Johns A, Grogan M, Bertino EM, He K, Shields PG, Kalemkerian GP, Gadgeel SM, Ramnath N, Schneider BJ, Hassan KA, Szerlip N, Chopra Z, Journey S, Waninger J, Spakowicz D, Carbone DP, Presley CJ, Otterson GA, Green MD, Owen DH. Qin A, et al. Among authors: he k. J Natl Compr Canc Netw. 2021 Apr 20;19(8):915-921. doi: 10.6004/jnccn.2020.7668. J Natl Compr Canc Netw. 2021. PMID: 33878726 Free PMC article.
Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy.
Guo Y, Wei L, Patel SH, Lopez G, Grogan M, Li M, Haddad T, Johns A, Ganesan LP, Yang Y, Spakowicz DJ, Shields PG, He K, Bertino EM, Otterson GA, Carbone DP, Presley C, Kulp SK, Mace TA, Coss CC, Phelps MA, Owen DH. Guo Y, et al. Among authors: he k. Clin Lung Cancer. 2022 Jun;23(4):345-355. doi: 10.1016/j.cllc.2021.12.010. Epub 2022 Jan 8. Clin Lung Cancer. 2022. PMID: 35131184 Free PMC article.
Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer.
Wong A, Riley M, Zhao S, Zimmer J, Viveiros M, Wang JG, Esguerra V, Li M, Lopez G, Kendra K, Carbone DP, He K, Alahmadi A, Kaufman J, Memmott RM, Shields PG, Brownstein J, Haglund K, Welliver M, Otterson GA, Presley CJ, Wei L, Owen DH, Ho K. Wong A, et al. Among authors: he k. J Natl Compr Canc Netw. 2023 Nov;21(11):1164-1171.e5. doi: 10.6004/jnccn.2023.7059. J Natl Compr Canc Netw. 2023. PMID: 37935100
DLL3: an emerging target in small cell lung cancer.
Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K. Owen DH, et al. Among authors: he k. J Hematol Oncol. 2019 Jun 18;12(1):61. doi: 10.1186/s13045-019-0745-2. J Hematol Oncol. 2019. PMID: 31215500 Free PMC article. Review.
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.
Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, Hummel HD, Borghaei H, Johnson ML, Steeghs N, Blackhall F, Dowlati A, Reguart N, Yoshida T, He K, Gadgeel SM, Felip E, Zhang Y, Pati A, Minocha M, Mukherjee S, Goldrick A, Nagorsen D, Hashemi Sadraei N, Owonikoko TK. Paz-Ares L, et al. Among authors: he k. J Clin Oncol. 2023 Jun 1;41(16):2893-2903. doi: 10.1200/JCO.22.02823. Epub 2023 Jan 23. J Clin Oncol. 2023. PMID: 36689692 Free PMC article. Clinical Trial.
4,699 results